Alcon Research

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alcon Research sits in the top decile of US sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count).

275 total trials 5 currently recruiting 248 completed later-stage tilt top decile by trial count

Alcon Research: 275 sponsored US clinical trials, 5 recruiting.

Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.

Top-decile sponsor footprint

Alcon Research ranks in the top decile of sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

248 of 266 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

275 total, page 4 of 6

COMPLETED

Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora

NCT01027494

COMPLETED NA

Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution

NCT01341977

COMPLETED NA

Effect of an Investigational Multi-Purpose Solution on Lens Moisture

NCT01341990

COMPLETED NA

Comparison of OPTI-FREE RepleniSH and ReNu Multi-Plus Lens Care Regimens on Corneal Epithelium

NCT00724269

COMPLETED Phase 4

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

NCT00979615

COMPLETED NA

ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)

NCT00967473

COMPLETED NA

Clinical Evaluation of the Causes of Contact Lens Related Dry Eye

NCT00995189

COMPLETED Phase 4

Presbyopia-Correcting Intraocular Lenses (IOLs)

NCT00963560

TERMINATED Phase 3

Macular Edema Incidence/Severity Reduction With Nevanac

NCT00939276

COMPLETED Phase 4

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195

COMPLETED Phase 4

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

NCT00800540

COMPLETED Phase 4

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery

NCT00818844

COMPLETED

Assessment of Visual Performance in Patients With Low Levels of Astigmatism

NCT00842231

COMPLETED

Corneal Astigmatism Measurement Study

NCT00818532

COMPLETED Phase 4

Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL

NCT00818116

TERMINATED Phase 2

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541

COMPLETED NA

Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients

NCT00799422

COMPLETED Phase 4

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

NCT00789555

COMPLETED Phase 4

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

NCT00772304

COMPLETED Phase 4

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577

COMPLETED Phase 4

Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1

NCT00710931

COMPLETED Phase 2

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144

COMPLETED NA

A Multi-Center Investigation of Patient Acceptability of OPTI-FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

NCT00772707

COMPLETED Phase 4

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103

COMPLETED NA

Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops

NCT00756093

COMPLETED NA

Phaco Versus Small Incision Cataract Surgery (SICS) Health Economic Study

NCT00762606

COMPLETED

Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green

NCT00768898

COMPLETED NA

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865

COMPLETED Phase 2

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717

COMPLETED NA

Evaluation of SYSTANE Ultra Lubricant Eye Drops

NCT00702377

COMPLETED Phase 1

Tobramycin Tear Concentrations

NCT00695435

COMPLETED NA

Acute Comfort of Lubricant Eye Drops FID 112903

NCT00673855

COMPLETED NA

Rotational Stability of the AcrySof® Toric

NCT00762216

COMPLETED Phase 4

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

NCT00691665

COMPLETED Phase 4

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

NCT00763360

COMPLETED NA

The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance

NCT00673764

COMPLETED NA

Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina

NCT00691457

COMPLETED NA

Evaluation of Deposits on Contact Lenses Worn Extended Wear

NCT00725530

COMPLETED

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

NCT00691639

COMPLETED NA

Evaluation of Deposits on Contact Lenses Worn Daily Wear

NCT00725153

COMPLETED Phase 2

24 Hour IOP Lowering Efficacy of AL-3789

NCT00643669

COMPLETED

Blue Light Intraocular Lenses (IOLs) and Photostress

NCT00710996

COMPLETED NA

Evaluation of Daily Disposable Lenses With Multi-Purpose Solution (MPS)

NCT00733291

TERMINATED

The Natural History of Geographic Atrophy Progression (GAP) Study

NCT00599846

TERMINATED Phase 2

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020

COMPLETED Phase 2

Adjunctive Study of AL-37807 Ophthalmic Suspension

NCT00620256

COMPLETED Phase 4

Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL

NCT00934622

COMPLETED Phase 3

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

NCT00576251

COMPLETED NA

Wettability of Contact Lenses With a Multi-Purpose Solution

NCT00713076

COMPLETED Phase 4

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

NCT00759941

← Previous Page 4 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 23
Phase 3 47
Phase 4 40

Where Alcon Research enrollment is open (later-stage tilt)

5 recruiting of 275 indexed (2% open); 248 completed (90%).

Phase mix: 87 late (III/IV) vs 28 early (I/II) (later-stage heavy).

Top condition: Cataract (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alcon Research: open-pipeline peers nationwide

Peers matched on 275 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15%20%25% Total trials Recruiting share Alcon ResearchBoston Scientific CorporationRegeneron PharmaceuticalsSWOG Cancer Research NetworkNovartisLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLexicon PharmaceuticalsSociété des Produits Nestlé (SPN)Eisai
Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 275 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

What to do with this Alcon Research page

275 registered trials is a research-attention snapshot, not an endorsement of Alcon Research or any single study.

  • 5 of Alcon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cataract is the condition Alcon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alcon Research pipeline card: 275 registered trials from official public datasets.Report a data error.